11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires a sufficient number of patients to have died, which may take a long time.
Progression-free survival is the surrogate most often used in oncology, but does not always satisfy the correlation conditions for surrogacy.
Davis et al. previously reviewed the use of surrogate end points in oncology, using papers published between 2001 and 2011. We extend this, reviewing papers published between 2012 and 2016. We also examine the reporting of statistical methods to assess the strength of surrogacy.